Profund Advisors LLC Exact Sciences Corp Transaction History

Profund Advisors LLC

  • $2.59 Billion
  • Q3 2024

A detailed history of Profund Advisors LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Profund Advisors LLC holds 48,869 shares of EXAS stock, worth $2.42 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
48,869
Previous 78,589 37.82%
Holding current value
$2.42 Million
Previous $3.32 Million 0.21%
% of portfolio
0.13%
Previous 0.13%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$42.43 - $70.83 $1.26 Million - $2.11 Million
-29,720 Reduced 37.82%
48,869 $3.33 Million
Q2 2024

Aug 13, 2024
BUY
$41.33 - $74.26 $2.29 Million - $4.12 Million
55,459 Added 239.77%
78,589 $3.32 Million
Q1 2024

May 08, 2024
BUY
$56.27 - $73.77 $68,536 - $89,851
1,218 Added 5.56%
23,130 $1.6 Million
Q4 2023

Feb 14, 2024
BUY
$59.06 - $75.72 $192,004 - $246,165
3,251 Added 17.42%
21,912 $1.62 Million
Q3 2023

Nov 13, 2023
BUY
$65.94 - $99.04 $122,978 - $184,709
1,865 Added 11.1%
18,661 $1.27 Million
Q2 2023

Aug 10, 2023
SELL
$62.68 - $95.05 $197,442 - $299,407
-3,150 Reduced 15.79%
16,796 $1.58 Million
Q1 2023

May 11, 2023
BUY
$47.19 - $70.77 $5,993 - $8,987
127 Added 0.64%
19,946 $1.35 Million
Q4 2022

Feb 02, 2023
BUY
$30.35 - $53.15 $15,933 - $27,903
525 Added 2.72%
19,819 $981,000
Q3 2022

Nov 04, 2022
SELL
$31.97 - $49.37 $25,831 - $39,890
-808 Reduced 4.02%
19,294 $627,000
Q2 2022

Aug 01, 2022
SELL
$35.61 - $76.23 $54,625 - $116,936
-1,534 Reduced 7.09%
20,102 $792,000
Q1 2022

May 10, 2022
SELL
$57.56 - $82.54 $118,516 - $169,949
-2,059 Reduced 8.69%
21,636 $1.51 Million
Q4 2021

Feb 08, 2022
SELL
$72.5 - $100.68 $303,557 - $421,547
-4,187 Reduced 15.02%
23,695 $1.84 Million
Q3 2021

Nov 12, 2021
SELL
$90.24 - $124.05 $126,065 - $173,297
-1,397 Reduced 4.77%
27,882 $2.66 Million
Q2 2021

Aug 12, 2021
SELL
$93.66 - $139.27 $47,672 - $70,888
-509 Reduced 1.71%
29,279 $3.64 Million
Q1 2021

May 14, 2021
SELL
$116.57 - $155.01 $305,180 - $405,816
-2,618 Reduced 8.08%
29,788 $3.93 Million
Q4 2020

Feb 09, 2021
BUY
$99.61 - $142.12 $448,045 - $639,255
4,498 Added 16.12%
32,406 $4.29 Million
Q3 2020

Nov 13, 2020
SELL
$72.92 - $102.01 $263,824 - $369,072
-3,618 Reduced 11.48%
27,908 $2.85 Million
Q2 2020

Aug 03, 2020
BUY
$55.75 - $92.75 $292,353 - $486,381
5,244 Added 19.95%
31,526 $2.74 Million
Q1 2020

May 15, 2020
SELL
$37.9 - $104.44 $363,271 - $1 Million
-9,585 Reduced 26.72%
26,282 $1.52 Million
Q4 2019

Feb 18, 2020
BUY
$77.66 - $99.74 $471,163 - $605,122
6,067 Added 20.36%
35,867 $3.32 Million
Q3 2019

Nov 12, 2019
SELL
$90.37 - $122.49 $181,734 - $246,327
-2,011 Reduced 6.32%
29,800 $2.69 Million
Q2 2019

Aug 13, 2019
SELL
$89.51 - $118.04 $288,938 - $381,033
-3,228 Reduced 9.21%
31,811 $3.76 Million
Q1 2019

May 15, 2019
BUY
$61.98 - $96.5 $79,024 - $123,037
1,275 Added 3.78%
35,039 $3.04 Million
Q4 2018

Feb 14, 2019
SELL
$56.04 - $82.66 $459,135 - $677,233
-8,193 Reduced 19.53%
33,764 $2.13 Million
Q3 2018

Nov 13, 2018
BUY
$48.29 - $80.6 $198,520 - $331,346
4,111 Added 10.86%
41,957 $3.31 Million
Q2 2018

Aug 13, 2018
SELL
$37.84 - $69.96 $199,492 - $368,829
-5,272 Reduced 12.23%
37,846 $2.26 Million
Q1 2018

May 14, 2018
SELL
$39.82 - $57.53 $166,567 - $240,647
-4,183 Reduced 8.84%
43,118 $1.74 Million
Q4 2017

Feb 14, 2018
SELL
$46.49 - $60.51 $230,032 - $299,403
-4,948 Reduced 9.47%
47,301 $2.49 Million
Q3 2017

Nov 13, 2017
BUY
$37.05 - $47.12 $1.94 Million - $2.46 Million
52,249
52,249 $2.46 Million

Others Institutions Holding EXAS

# of Institutions
671
Shares Held
163M
Call Options Held
2.58M
Put Options Held
2.19M
View Full List

About EXACT SCIENCES CORP

EXAS Quotes by TradingView
  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $8.77B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Profund Advisors LLC Portfolio

Follow Profund Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email